With four Phase III trials of Epidiolex (cannabidiol, or CBD) in various forms of pediatric epilepsy, two for Dravet syndrome and two for LennoxGastaut syndrome (LGS) expected to provide top-line readouts in 2016 (three in H116), investors are understandably laser focused on these programs. Based on an analysis of the previous results of other molecules in Dravet and LGS, as well as data from the expanded access program, we are confident the trials are sufficiently powered to demonstrate a statistically significant benefit for patients taking Epidiolex